ABSTRACT
Near infra-red (NIR) self-guided photo-polymerization is investigated in the context of micro-optics photo-fabrication on VCSELs (Vertical-Cavity Surface Emitting Lasers). We present the optimized process we have developed to allow for a collective fabrication on III-V devices wafers under real-time optical monitoring. The influence of photo-chemical parameters on final micro-elements dimensions is studied for two types of single mode 760 nm VCSELs. The difference of the resulting tip shape between the two lasers is due to the strong differences of their emissions, as they are nicely reproduced by the computed near-field profiles. The tip shapes are also compared to those produced by the light emitted by an optical fiber and differences with VCSEL tips are discussed. Also the VCSEL characteristics with fabricated tips are discussed and found in good agreement with optical modeling.
Subject(s)
Lasers, Semiconductor , Molecular Imprinting/methods , Polymers/chemistry , Polymers/radiation effects , Infrared Rays , Refractometry , Surface PropertiesABSTRACT
In the natural environment, most of the phages that target bacteria are thought to exist in biofilm ecosystems. The purpose of this study was to gain a clearer understanding of the reactivity of these viral particles when they come into contact with bacteria embedded in biofilms. Experimentally, we quantified lactococcal c2 phage diffusion and reaction through model biofilms using in situ fluorescence correlation spectroscopy with two-photon excitation. Correlation curves for fluorescently labeled c2 phage in nonreacting Stenotrophomonas maltophilia biofilms indicated that extracellular polymeric substances did not provide significant resistance to phage penetration and diffusion, even though penetration and diffusion were sometimes restricted because of the noncontractile tail of the viral particle. Fluctuations in the fluorescence intensity of the labeled phage were detected throughout the thickness of biofilms formed by c2-sensitive and c2-resistant strains of Lactococcus lactis but could never be correlated with time, revealing that the phage was immobile. This finding confirmed that recognition binding receptors for the viral particles were present on the resistant bacterial cell wall. Taken together, our results suggest that biofilms may act as "active" phage reservoirs that can entrap and amplify viral particles and protect them from harsh environments.
Subject(s)
Bacteriophages/physiology , Biofilms/growth & development , Lactococcus/virology , Spectrometry, Fluorescence/methods , Virus Physiological Phenomena , Diffusion , Lactococcus/physiology , Stenotrophomonas/virologyABSTRACT
The effects of sodium hypochlorite (NaOCl) and peracetic acid/hydrogen peroxide (PAH) on the inactivation of adherent Listeria monocytogenes LO28 cells were examined. The surfaces tested were stainless steel and polytetrafluoroethylene (PTFE) conditioned or not with an anionic biosurfactant produced by Pseudomonas fluorescens. Dilution-neutralization methods were used to assess the effectiveness of sanitizer solutions on planktonic and adherent cells. Tests were performed on L. monocytogenes cultivated at 37 degrees Celsius (body temperature) or 20 degrees Celsius (ambient temperature). The results demonstrated that i) a total deficiency in nutrients induced by the incubation of cells in 0.15 M NaCl favored the action of NaOCl and PAH on planktonic cells; ii) by reducing the number of cells adhering to stainless steel, pre-conditioning of the surface with the biosurfactant reduced the level of contamination of the surface and thus favored the bactericidal activities of the disinfectants; and iii) the weak binding energies involved in the adsorption of the biosurfactant on PTFE surfaces resulted in there being no reduction by the polymer of the surface contamination. Furthermore, this study confirmed that adherent cells exhibited increased resistance to the actions of the disinfectants when compared to the resistance of planktonic cells.
Subject(s)
Bacterial Adhesion , Disinfectants/pharmacology , Disinfection/methods , Listeria monocytogenes/growth & development , Surface-Active Agents/pharmacokinetics , Adsorption , Drug Resistance, Bacterial , Equipment Contamination , Hydrogen Peroxide/pharmacology , Listeria monocytogenes/drug effects , Listeria monocytogenes/physiology , Peracetic Acid/pharmacology , Polytetrafluoroethylene , Pseudomonas fluorescens/growth & development , Pseudomonas fluorescens/metabolism , Sodium Hypochlorite/pharmacology , Stainless Steel , Surface Properties , TemperatureABSTRACT
Osteopontin (OPN), an RGD-containing extracellular matrix protein, is associated with arterial smooth muscle cell (SMC) activation in vitro and in vivo. Many cytokines and growth factors involved in vessel wall remodeling induce OPN overexpression. Moreover, we recently demonstrated that the extracellular nucleotide UTP also induces OPN expression and that OPN is essential for UTP-mediated SMC migration. Thus, we set out to investigate the mechanisms of OPN expression. The aim of this study was to identify transcription factors involved in the regulation of OPN expression in SMCs. First, we explored the contribution of mRNA stabilization and transcription in the increase of UTP-induced OPN mRNA levels. We show that UTP induced OPN mRNA increases via both OPN mRNA stabilization and OPN promoter activation. Then, to identify transcription factors involved in UTP-induced OPN transcription, we located a promoter element activated by UTP within the rat OPN promoter using a gene reporter assay strategy. The -96 to +1 region mediated UTP-induced OPN overexpression (+276+/-60%). Sequence analysis of this region revealed a potential site for AP-1 located at -76. When this AP-1 site was deleted, UTP-induced activation of the -96 to +1 region was totally inhibited. Thus, this AP-1 (-76) site is involved in UTP-induced OPN transcription. A supershift assay revealed that both c-Fos and c-Jun bind to this AP-1 site. Finally, we demonstrate that angiotensin II and platelet-derived growth factor, two main factors involved in vessel wall pathology, also modulated OPN expression via AP-1 activation.
Subject(s)
Muscle, Smooth, Vascular/drug effects , Sialoglycoproteins/genetics , Transcription Factor AP-1/metabolism , Uridine Triphosphate/pharmacology , Angiotensin II/pharmacology , Animals , Aorta, Thoracic/cytology , Binding Sites/genetics , Blotting, Northern , Cells, Cultured , Electrophoretic Mobility Shift Assay , Gene Expression Regulation/drug effects , Luciferases/genetics , Luciferases/metabolism , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/metabolism , Osteopontin , Platelet-Derived Growth Factor/pharmacology , Promoter Regions, Genetic/genetics , Protein Binding , Proto-Oncogene Proteins c-fos/metabolism , Proto-Oncogene Proteins c-jun/metabolism , RNA Stability/drug effects , RNA, Messenger/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Wistar , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Regulatory Sequences, Nucleic Acid/genetics , Time Factors , Transcription, Genetic/drug effectsABSTRACT
Osteopontin (OPN), an RGD containing extracellular matrix protein, is associated with arterial smooth muscle cells (SMC) activation in vitro and in vivo. OPN has been shown to be overexpressed in vascular injury. Its expression can be induced by many factors including growth factors, cytokines, hormones and extracellular nucleotides. We are interested in understanding mechanisms regulating the OPN mRNA steady state level in SMC. We compared the effect of two G-protein coupled receptors agonists (UTP and angiotensin II [AII]) and one tyrosin kinase receptor agonist (PDGF). We explored the effect of these three agonists both on OPN transcription using gene reporter assay and on OPN mRNA stabilisation using actinomycin D. We showed that UTP 100 microM. AII 10 microM and PDGF 50 ng/microL induced OPN transcription. Whereas UTP and AII induced a 366 +/- 81% and 338 +/- 115% activation of transcription respectively, PDGF demonstrated a lower efficiency (195 +/- 59%) inducing the transcription. Moreover, we demonstrated that UTP and AII but not PDGF were able to stabilize OPN mRNA. This effect seems to be specific to G-protein coupled receptor agonists since previous studies demonstrated that intracellular receptor agonists did not stabilise OPN mRNA. Thus, the lower increase of OPN mRNA level in response to PDGF stimulation compared to AII or UTP could be explain by both, the lower activation of the OPN promoter and the effect of UTP and AII on OPN mRNA stabilisation.
Subject(s)
Angiotensin II/pharmacology , Arteries/physiology , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/physiology , Platelet-Derived Growth Factor/pharmacology , Sialoglycoproteins/biosynthesis , Vasoconstrictor Agents/pharmacology , Animals , Cell Adhesion , Cytokines , GTP-Binding Proteins , Gene Expression Profiling , Genes, Reporter , Osteopontin , Phosphoproteins , RNA, Messenger/analysis , Rats , Rats, Wistar , Receptors, Cell Surface , Uridine TriphosphateABSTRACT
Migration and proliferation of arterial smooth muscle cells (SMCs) play a prominent role in the development of atherosclerotic plaques and restenosis lesions. Most of the growth-regulatory molecules potentially involved in these pathological conditions also demonstrate chemotactic properties. Extracellular purine and pyrimidine nucleotides have been shown to induce cell cycle progression and to elicit growth of cultured vascular SMCs. Moreover, the P2Y(2) ATP/UTP receptor was overexpressed in intimal thickening, suggesting a role of these nucleotides in vascular remodeling. Using the Transwell system migration assay, we demonstrate that extracellular ATP, UTP, and UDP exhibit a concentration-dependent chemotactic effect on cultured rat aortic SMCs. UTP, the most powerful nucleotide inducer of migration, elicited significant responses from 10 nmol/L. In parallel, UTP increased osteopontin expression dose-dependently. The blockade of osteopontin or its integrin receptors alpha(v)beta(3)/beta(5) by specific antibodies or antagonists inhibited UTP-induced migration. Moreover, the blockade of ERK-1/ERK-2 MAP kinase or rho protein pathways led to the inhibition of both UTP-induced osteopontin increase and migration, demonstrating the central role of osteopontin in this process. Taken together, these results suggest that extracellular nucleotides, and particularly UTP, can induce arterial SMC migration via the action of osteopontin.
Subject(s)
Cell Movement/physiology , Extracellular Space/metabolism , Muscle, Smooth, Vascular/metabolism , Nucleotides/pharmacology , Sialoglycoproteins/metabolism , Adenosine Diphosphate/pharmacology , Adenosine Triphosphate/pharmacology , Animals , Aorta , Calcium/metabolism , Cell Movement/drug effects , Cells, Cultured , Chemotaxis/drug effects , Chemotaxis/physiology , Diffusion Chambers, Culture , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Intracellular Signaling Peptides and Proteins , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinases/metabolism , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/drug effects , Oligopeptides/pharmacology , Osteopontin , Phosphorylation/drug effects , Protein Serine-Threonine Kinases/antagonists & inhibitors , Protein Serine-Threonine Kinases/metabolism , Rats , Rats, Wistar , Uridine Diphosphate/pharmacology , Uridine Triphosphate/pharmacology , rho-Associated Kinases , rhoA GTP-Binding Protein/metabolismABSTRACT
The aim of the present study was to examine the relationships between ambulatory blood pressure (ABPM) and urinary albumin excretion (UAE) in diabetic (non-insulin dependent [NIDDM] and insulin-dependent [IDDM]) hypertensives at baseline and after treatment by an angiotensin converting enzyme (ACE) inhibitor. After a 3-week placebo period, patients were treated for 16 weeks with trandolapril, 2 to 4 mg/day. The UAE and blood pressure (mercury sphygmomanometer and 24-h ABPM) were measured at baseline and repeated on trandolapril. Predictive factors of abnormal UAE (24-h UAE > or = 30 mg) were determined using univariate and multivariate analysis (logistic regression). Predictors of UAE decrease were also searched. One hundred seventy-one patients entered the analysis. Baseline office BP was 164+/-14 / 97+/-6 mm Hg and 24-h BP was 142+/-17 / 83+/-10 mm Hg. Seventy-four patients (43%) had UAE > or = 30 mg. Independent risk factors for abnormal UAE were nighttime diastolic BP (odds ratio [OR] = 4.1, confidence interval [CI] = 2.0 to 8.6, P = .0001), diabetes duration (OR = 2.4, CI = 1.1 to 5.0, P = .025), and presence of retinopathy (OR = 3.2, CI = 1.0 to 10.0, P = .047). Conversely, office BP level was not significantly related to UAE. On treatment, office BP levels decreased to 143+/-13 / 82+/-8 mm Hg (P < .0001) and 24-h BP levels to 134+/-17 / 78+/-9 mm Hg (P < .0001). In the abnormal UAE group, UAE significantly decreased from 76 to 50 mg/day (P = .006). After treatment, independent predictive factors of abnormal UAE were: on-drug fasting plasma glucose (OR = 3.5, CI = 1.7 to 7.4, P = .0009) and on-drug nighttime diastolic BP (OR = 3.5, CI = 1.7 to 7.4, P = .001). The only predictor of UAE decrease was a 24-h systolic BP decrease (OR = 2.3, CI = 1.3 to 4.3, P = .007). We conclude that in diabetic hypertensives with abnormal UAE, trandolapril exhibited a sustained 24-h antihypertensive effect and provided a consistent reduction of microalbuminuria. This study confirmed the superiority of ABPM over clinical BP to predict target organ damage.
Subject(s)
Albuminuria/physiopathology , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Blood Pressure , Diabetes Mellitus, Type 1/physiopathology , Diabetes Mellitus, Type 2/physiopathology , Hypertension/drug therapy , Hypertension/physiopathology , Indoles/therapeutic use , Blood Pressure/drug effects , Blood Pressure Monitoring, Ambulatory , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/urine , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/urine , Humans , Hypertension/complications , Hypertension/urineABSTRACT
OBJECTIVES: This survey sought to determine actual practices in the management of acute myocardial infarction on a nationwide scale. BACKGROUND: Few data are available regarding the adoption of clinical trial results of treatment of myocardial infarction into "real-world" clinical practice. METHODS: Of 501 intensive care units in France, 373 (74%) collected data from all patients with myocardial infarction admitted within 48 h of symptom onset during November 1995. RESULTS: Data from 2,563 patients (71% men; mean age [+/-SD] 67 +/- 14 years) were included. Time from symptom onset to admission was <6 h in 1,467 patients (62%). Thrombolysis was used in 822 patients (32%) and primary angioplasty in 330 (13%). The use of reperfusion therapy decreased markedly with age. During the first 5 days, heparin was prescribed in 96% of patients, aspirin in 89%, nitrates in 87%, beta-adrenergic blocking agents in 64%, angiotensin-converting enzyme inhibitors in 46% and calcium antagonists in 17%. Coronary angiography was performed in 33% of patients, and 58% had echocardiographic assessment of left ventricular ejection fraction (LVEF). Median LVEF was 50%. The 5-day mortality rate was 7.7% compared with 12.1% in a previous French survey carried out in 1984. By multivariate analysis, independent predictors of mortality were age, anterior infarction, history of stroke and heart failure and, when added to the model, Killip class and LVEF. CONCLUSIONS: This survey shows that the results of therapeutic trials have largely translated to clinical practice, resulting in improved early outcome compared with the early 1980s. However, continuous efforts should be made to shorten the time delay before hospital admission and to increase the proportion of elderly patients receiving reperfusion therapy.
Subject(s)
Myocardial Infarction/therapy , Practice Patterns, Physicians' , Aged , Female , France/epidemiology , Hospital Mortality , Humans , Intensive Care Units , Male , Myocardial Infarction/mortality , Myocardial Reperfusion/statistics & numerical data , Patient Admission/statistics & numerical data , Practice Patterns, Physicians'/statistics & numerical data , Prospective Studies , Risk Factors , Thrombolytic Therapy/statistics & numerical data , Time Factors , Treatment OutcomeABSTRACT
OBJECTIVES: To analyze the circadian pattern of the first signs of myocardial infarction in France. METHODS: The USIK study was conducted in November 1995 among patients hospitalized in cardiac intensive care units within 48 hours after the first signs of confirmed myocardial infarction. This prospective study recorded the day and hour of onset for each eligible patient. RESULTS: Three hundred seventy-three centers throughout France participated, including 2563 patients (71% men), mean age 68 years, with confirmed myocardial infarction. The day of the week in which the first signs occurred was recorded between November 3 and 30, 1995. The pattern did not show any peaks, notably on Monday as reported in the literature. The hour of onset was known in 2468 patients (96.3%). Demographic features and past history did not vary for the overall population. Hour of onset was: between midnight and 6 a.m. 20.1%; between 6 and 12 a.m. 30.6%; between noon and 6 p.m. 25.7%; between 6 p.m. and midnight 23.6% (p < 0.001). This pattern was also studied in several subgroups of patients defined by age, sex, presence or absence of different cardiovascular risk factors or pertinent cardiovascular history. Univariate analysis showed that the distribution in the 6 a.m.-noon period was significantly different by age group. Older patients had a higher morning peak than younger patients (32.6% versus 28.7%; p = 0.03). Inversely, this peak was lower in smokers compared with non-smokers (26.7% versus 32.4%; p = 0.005); likewise, in patients with recurrent infarction compared with first infarction patients (24.7% versus 31.9%; p = 0.003). Other variables did not affect the circadian pattern. After multivariate analysis, only 2 of these 3 factors had an influence on distribution in the 6-12 a.m. period: smoking habits (odds ratio = 0.75; p < 0.01) and prior myocardial infarction (odds ratio = 0.70; p < 0.01). CONCLUSION: This large epidemiology study confirms that there is a morning peak in the circadian pattern of myocardial infarction in France. Smoking and past history of infarction significantly affect the circadian pattern.
Subject(s)
Circadian Rhythm , Myocardial Infarction/epidemiology , Aged , Demography , Female , France/epidemiology , Humans , Intensive Care Units , Male , Mass Screening , Middle Aged , Myocardial Infarction/physiopathology , Prospective Studies , Risk Factors , SmokingABSTRACT
Patients admitted in coronary care units, in november 1995, for confirmed acute myocardial infarction within 48 hours of symptoms onset were included in this study. The choice of measurement of left ventricular ejection fraction (LVEF) was left to the physician in charge. Only investigations performed within the first 8 days were taken into consideration. In cases with multiple investigations, the following order of preference was applied: a) angiographic LVEF, b) isotopic LVEF, c) echocardiographic ejection fraction by Simpson's method, d) echocardiographic ejection fraction by Berning's method, e) semi-quantitative visual echocardiographic evaluation. 2563 patients were included (1827 males and 736 females, mean age 67 years). A quantitative evaluation of LVEF was obtained in 1477 patients (57%) whereas 2 053 patients (80%) underwent at least a semi-quantitative evaluation. The average LVEF was 50% and 17% of patients had an ejection fraction < or = 35%. Patients with LVEF < or = 35% were older, less likely males, non smokers and diabetics. Prior heart failure, previous myocardial infarction and anterior location in infarction were more frequent. Heart failure was more frequent in patients with LVEF < or = 35% (75 vs 23%, p < 0.001). One hundred and ninety-seven patients (7.7%) died in the five first days following the onset of symptoms. A left ventricular ejection fraction < or = 35% multiplied the risk of death by 8.1 (Confidence interval: 5.7-11.4, p < 0.001). The presence of clinical heart failure increased the risk even more.
Subject(s)
Myocardial Infarction/epidemiology , Ventricular Dysfunction, Left/diagnosis , Aged , Aged, 80 and over , Coronary Care Units , Female , France/epidemiology , Hospital Mortality , Humans , Male , Middle Aged , Myocardial Infarction/complications , Myocardial Infarction/therapy , Risk Factors , Stroke Volume , Treatment Outcome , Ventricular Dysfunction, Left/complications , Ventricular Dysfunction, Left/mortalityABSTRACT
A national epidemiological study undertaken in November 1995 recensed the data of 2563 patients admitted to 373 Intensive Care Units for acute myocardial infarction. There were 1827 men and 736 women with an average age of 67 years. Seventeen per cent of patients had left ventricular ejection fration (LVEF) < or = 35%. The mortality rate at 5 days was 7.7%. Clinical heart failure (Killip > 1) was observed in 34.4% of patients. 63% of patients were admitted before the 6th hour. Forty-six per cent of patients underwent early revascularisation by thrombolysis and/or angioplasty. The most widely used drugs in the first 5 days were heparin (96%), aspirin (89%), betablockers (65%), and angiotension converting enzyme inhibitors (46%). The influence of region on the demographical features, morbidity, mortality and therapeutic practice was studied. France was divided into 6 regions. In the Centre, the patients were older, with increased morbidity and mortality compared with the national average. Patients in the North East were similar and had a higher incidence of obesity. In the Ile de France, patients were generally younger with a higher incidence of tobacco consumption and their infarcts were generally less severe. Finally, in the South East, the mortality was particularly low. In multivariate analysis living in this region was good prognostic factor whereas low LVEF (< or = 35%) and age > or = 65 years were poor prognostic factors. This study, for the first time in France, describes the clinical features of myocardial infarction admitted to the Intensive Care Unit with respect to criteria of severity (LVEF, Killip) and region of origin of the patients. Its confirms large regional variations in the severity of acute myocardial infarction.
Subject(s)
Myocardial Infarction/epidemiology , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Coronary Care Units/statistics & numerical data , Data Interpretation, Statistical , Female , France/epidemiology , Humans , Male , Middle Aged , Myocardial Infarction/complications , Myocardial Infarction/therapy , Population Surveillance , Prospective Studies , Risk Factors , Sex DistributionABSTRACT
OBJECTIVE: This study was designed to assess the compliance of hypertensive patients with a once-daily regimen of the angiotensin converting enzyme (ACE) inhibitor trandolapril and to evaluate the antihypertensive efficacy of the drug in relation to the time interval between taking the final dose and measuring the blood pressure (BP). DESIGN: After a 2-week wash-out period, hypertensive patients, recruited by cardiologists, received trandolapril 2 mg once daily in the morning for 4 weeks. METHODS: In order to assess compliance, each patient's supply of trandolapril capsules was presented in a pillbox that incorporated in its lid a microprocessor that recorded the date and time of each occasion that it was opened. BP was measured using validated semi-automatic devices, at the end of both the wash-out and the treatment period. RESULTS: A total of 590 patients entered the study. Compliance data were evaluable for 501 patients. Overall compliance, defined as the ratio of the number of openings recorded to the number of doses prescribed was less than 80, 80-100, and more than 100% in 17, 63 and 20% of patients, respectively. The average number (+/- SD) of missed doses was 4.5 +/- 8 (median 2). The average interval between successive openings was 25 h 07 min mean +/- 13 h (median 24 h). The average number of delayed doses (a delayed dose being defined as the box being opened 25-36 h after the previous occasion) was 5.6 +/- 3 (median 6). Patients living in the Paris area had more forgotten and delayed doses than those living in the provinces (7.9 versus 3.8 forgotten; P<0.0001 and 6.3 versus 5.5 delayed; P<0.005). Doses were forgotten and delayed more often during weekends than on weekdays. The greatest number of delayed doses occurred in those patients under 60 years of age (6.0 versus 5.2; P<0.01). Decreases in systolic blood pressure (SBP and diastolic blood pressure (DBP) were 20.3/12.8 mmHg, for patients whose final drug was taken on the same day as the BP measurement, and 18.9/11.2 mmHg for patients whose final dose was taken on the previous day. CONCLUSIONS: Electronic compliance monitoring allows refined analysis of the behaviour of hypertensive patients. In this study doses were missed and delayed frequently during the first month of treatment, depending on the patient's lifestyle.
Subject(s)
Electronics, Medical , Hypertension/psychology , Patient Compliance/psychology , Adolescent , Adult , Age Factors , Aged , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Antihypertensive Agents/administration & dosage , Blood Pressure/drug effects , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Evaluation , Drug Monitoring/psychology , Drug Packaging , Female , Follow-Up Studies , Humans , Hypertension/drug therapy , Hypertension/epidemiology , Incidence , Indoles/administration & dosage , Male , Middle Aged , Severity of Illness Index , Sex Factors , Statistics as Topic , Time Factors , Treatment OutcomeABSTRACT
The objective of the MACH1 study (MEMS for the Assessment of Compliance of Hypertensives) was to evaluate the real behaviour of patients in relation to antihypertensive treatment administered as a single daily dose. After a 2-week period during which no other antihypertensive was allowed to be administered, 590 patients with mild-to-moderate hypertension received 2 mg of trandolapril as a single daily dose in the morning between 7:00 a.m. and 9:00 a.m. for 4 weeks. Treatment was packaged in electronic pillboxes recording the date and time of each opening. Various profiles were distinguished on the basis of the individual chronograms for the 501 patients able to be analysed in terms of compliance, and as a function of the deviations observed in relation to the treatment regimen prescribed. One hundred and two patients (20%) omitted more than 20% of the prescribed doses, either consecutive doses or scattered throughout the month of treatment; these patients were referred to as "omitters". The other patients were classified according to the scatter of openings in relation to the mean time of the dose: 10 "metronome" patients (2%), 126 "regular" patients (25%), 221 "irregular" patients (44%) and 42 "anarchic" patients (8%). Irregularities of dose times were more frequent on public holidays than on week days and in patients living in Paris or the Paris region. "Metronome" patients were older than the overall patient population. The use of an electronic pillbox could allow the attending physician to more adequately adapt his therapeutic approach and management of specific problems of compliance observed in hypertensive patients.
Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Cooperative Behavior , Hypertension/psychology , Indoles/therapeutic use , Medication Systems , Patient Compliance , Adolescent , Adult , Aged , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Dose-Response Relationship, Drug , Female , France , Humans , Hypertension/drug therapy , Indoles/administration & dosage , Male , Middle AgedABSTRACT
The efficacy and tolerability of mifepristone in combination with misoprostol for termination of early pregnancy (up to 49 days of amenorrhea) are established. We studied the efficacy and tolerability of this combination therapy for termination of pregnancy in women up to 63 days of amenorrhea. We also examined the effect of an additional dose of misoprostol in cases of nonexpulsion within 3 hours after the first dose. The multicenter trial included 1,108 women, mean age 27.9 +/- 6.2 years. The mean duration of pregnancy was 51.7 +/- 9.2 days. On day 1, the women received an oral dose of mifepristone, 600 mg. On day 3, they received an oral dose of misoprostol, 400 micrograms, and were monitored for up to 3 hours. If they did not expel the conceptus within 3 hours, an additional dose of 200 micrograms of misoprostol was given and they were monitored for 2 more hours. From days 10 to 18, the women were followed up with clinical examination, human chorionic gonadotropin measurement, or ultrasound examination. Overall, the procedure was successful in 92.9% of women. Efficacy decreased with the duration of pregnancy, especially after 56 days of amenorrhea. Up to 42 days of amenorrhea, the success rate was 97.6%; between days 42 and 49, 94.8%; between days 50 and 56, 93.4%; between days 57 and 63, 86.8%; and after day 63, 83.3%. The most common side effects were moderate uterine cramps (80.5%) and gastrointestinal (GI) symptoms (34.9%), especially vomiting (18.3%) and diarrhea (10.5%). GI symptoms were generally mild. A second dose of misoprostol was given to 61.6% of the women. In a subgroup analysis, we assessed the efficacy of 600 mg of mifepristone plus 400 or 600 micrograms of misoprostol (one or two doses) in women with up to 49 days of amenorrhea and compared it with the efficacy in women who received mifepristone plus only 400 micrograms (one dose) of misoprostol in a previous study. The overall rate of success (termination of pregnancy) was 95.5% in the current study compared with 95.4% in the previous study. The additional dose of misoprostol did not significantly increase the overall rate of success, but did increase the rate of termination within the monitoring period (69.7% versus 64.9% (and within 72 hours after administration of mifepristone (92.7% versus 90.4%). We have confirmed that the combination of mifepristone and misoprostol was effective, safe, and well tolerated for termination of pregnancies at 49 or fewer days of amenorrhea. The efficacy decreased slightly between 49 and 56 days, and then decreased significantly between 56 and 63 days. For maximal safety and tolerability, we recommend this method only for women with 49 or fewer days of amenorrhea. A second dose of misoprostol did not improve overall efficacy, but did increase the rate of early termination.
Subject(s)
Abortifacient Agents/pharmacology , Amenorrhea/drug therapy , Menstruation-Inducing Agents/pharmacology , Mifepristone/pharmacology , Misoprostol/pharmacology , Pregnancy/drug effects , Abortifacient Agents/adverse effects , Abortifacient Agents/standards , Adolescent , Adult , Amenorrhea/physiopathology , Chorionic Gonadotropin/blood , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , France/epidemiology , Hemostatic Techniques , Humans , Incidence , Menstruation-Inducing Agents/adverse effects , Menstruation-Inducing Agents/standards , Mifepristone/adverse effects , Mifepristone/standards , Misoprostol/adverse effects , Misoprostol/standards , Pregnancy/blood , Pregnancy/physiology , Pregnancy, Ectopic/surgery , Time Factors , Ultrasonography , Uterine Hemorrhage/chemically induced , Uterine Hemorrhage/therapy , Uterus/diagnostic imaging , Uterus/physiologyABSTRACT
BACKGROUND AND METHODS: The combination of mifepristone (RU 486) and a prostaglandin analogue given either intramuscularly or intravaginally is effective in terminating early pregnancy, but the prostaglandin component of the regimen is cumbersome to administer and has side effects. We conducted two studies to determine the efficacy of 600 mg of mifepristone followed by a small dose of misoprostol, an orally active prostaglandin E1 analogue, for the same purpose. In the first study, 505 women who had had amenorrhea for less than 50 days received 400 micrograms of misoprostol 48 hours after receiving mifepristone, if the pregnancy was not terminated within that period. In the second study, 390 women initially received the same treatment, but if the pregnancy was not terminated within four hours after the administration of misoprostol, they were offered an additional 200-micrograms dose of misoprostol. RESULTS: In study 1, the rate of success (termination of pregnancy and complete expulsion of the conceptus) was 96.9 percent (95 percent confidence interval, 94.1 to 97.7 percent)--similar to the success rate of approximately 95 percent for mifepristone followed by the intramuscular or intravaginal administration of prostaglandin. Abortion occurred in 2.9 percent of the women within 48 hours after the administration of mifepristone, in 60.9 percent within 4 hours after the administration of misoprostol, and in 33.2 percent thereafter. The failures included ongoing pregnancies in four women (0.8 percent) and incomplete abortions in nine (1.8 percent); two other women (0.4 percent) required vacuum aspiration for prolonged uterine bleeding. In study 2, pregnancy was terminated in 5.5 percent of the women before the administration of misoprostol and within four hours after the first dose of misoprostol in 69.1 percent. Among the 71 women who received a second dose of misoprostol, 67 had complete abortions, 2 had partial retention of the conceptus, 1 had synechia with ongoing pregnancy, and 1 had an ectopic pregnancy. One ongoing pregnancy, which was terminated by vacuum aspiration, was recorded among the 27 women who declined to take the second dose of misoprostol. The overall rate of success of the regimen with the optional second dose of misoprostol was 98.7 percent (95 percent confidence interval, 96.8 to 99.5 percent). No woman had any serious adverse event. CONCLUSIONS: The combination of mifepristone and misoprostol is effective for the termination of early pregnancy in terms of success, tolerance, safety, and practicality.
PIP: Between June and October 1991 health workers administered 1 dose of 600 mg mifepristone (RU-486) and a single oral dose of 400 mcg misoprostol on day 3 to at least 488 women at 25 centers in France to terminate pregnancy of less than 50 days duration. Pregnancy termination occurred within 48 hours in 2.9% of all women. They had only received RU-486. 1% vomited after taking the first dose of misoprostol, necessitating a second dose. The overall success rate for this regimen was 96.9%. 12 hours was the mean time between taking misoprostol and expulsion of the conceptus. The median time was 3 hours. The types of failure were incomplete expulsion of the conceptus (1.8%), ongoing pregnancy (0.8%), and prolonged bleeding (0.4%). Mean duration of bleeding following the regimen was 9 days. A second study occurred between March 1991 and March 1992 among at least 385 women at 1 center in France. They received RU-486 and misoprostol in the same manner as the women in study 1, but those who did not experience pregnancy termination within 4 hours after the initial dose received another 200 mcg dose of misoprostol. 5/5% experienced pregnancy termination before administration of misoprostol. 69.1% experienced termination within 4 hours. Pregnancy termination occurred within the first 3 hours in almost 90% of them. 27 women who did not abort within 4 hours did not take the additional dose and 26 of them aborted completely. The sole woman with a continued pregnancy underwent vacuum aspiration. 67 of the 71 women who took the second dose completely expelled the conceptus within 48 hours. Thus, 79.2% of all women aborted while being monitored at the center. The overall success rate was 98.7% . The leading side effects in both studies in order of frequency were uterine cramps and nausea, vomiting, and diarrhea. These results showed that oral administration of misoprostol is as effective and well tolerated as other prostaglandins administered parenterally or vaginally.
Subject(s)
Abortion, Induced , Mifepristone/administration & dosage , Misoprostol/administration & dosage , Administration, Oral , Adult , Female , Humans , Injections, Intramuscular , Pregnancy , Pregnancy Trimester, FirstABSTRACT
We report the results of a large-scale trial with mifepristone (RU 486) followed by the administration of a prostaglandin (PG) analogue for the medical termination of early pregnancy. Altogether, 16,173 patients from 300 centers were evaluated. 48 women (0.3%) were lost to follow-up prior to, and 416 (2.6%) after the PG administration, and therefore the efficacy was evaluated in 15,709 women. Overall, the success rate was 95.3%, with no statistical difference regarding the nature and dose of PG used. The median duration of bleeding was 8 days, being 12 days or less in 89.7% of the women. Bleeding was significant enough to necessitate a vacuum aspiration or a dilatation and curettage in 0.8% of the cases. A blood transfusion was necessary in 0.1% of the women (11 patients). Serious cardio-vascular side-effects were reported in 4 cases after the PG (sulprostone) injection: they consisted of one acute myocardial infarction attributed to a coronary spasm, and in marked hypotension in the other 3 women. All patients recovered uneventfully. In conclusion, RU 486 followed by a PG analogue provides an efficient and safe medical alternative to surgery for early pregnancy termination, provided that the recommended protocol is adequately followed and the contraindications to prostaglandins are respected.
PIP: Between May 1988 and September 1989, physicians administered 600 mg of RU-486 followed by either 1 mg gemeprost vaginal pessary or im injection of 0.125-1.0 mg sulprostone to 16,369 11-48 year old women attending 30 centers in France to evaluate this regimen's safety and efficacy and whether trained prescribers could adequately comply with recommended protocol. 13.6% patients whose gestational age was greater than the recommended 50 days, underwent RU-486 and prostaglandin (PG) analogue administration. 78% of 571 patients did not receive a PG analogue because they expelled the conceptus after RU-486 administration. The remaining 126 women did not receive RU-486 even though they had not expelled the conceptus. Clinicians administered to PG analogue to 88.4% of all women within the recommended 36-48 hours after RU-486 administration. The RU-486 and PG analogue regimen had a success rate of 95.3%. Women who received the PG analogue within the recommended time period had a higher success rate than those who received it either too early or too late (95.8% vs. 92.8% and 93.9%, respectively; p = .001). In those women who did not receive the PG analogue, RU-486's success rate was considerably lower (88.6%; p .001). The nature and does of the PG analogue greatly influenced expulsion within 4 hours after its administration (44.1% after 1 mg gemeprost vs. 57.3%, 55.8%, 73.5%, and 67.6% after 0.125, 0.25, 0.375, and 0.5 mg sulprostone respectively; p .001). The higher doses of sulprostone had a significant effect on duration of bleeding (e.g., 9.1 days for 0.5 mg vs. 7.1 days for 0.125 mg p .001). 89.7% of the women bled for no more than 12 days. The bleeding was so profuse in 0.8% of the cases that either vacuum aspiration or dilatation and curettage was needed. 11 women required 1-3 units of blood. 8.5% experienced at least 1 side effect, the most common being uterine cramps (1.6% of all cases). 4 women suffered from grave cardiovascular effects (myocardial infarction in 1 case, severe hypotension in 3 cases). As long as prescribers consider contraindications and follow the protocol, this regimen is a viable alternative to surgical abortion.
Subject(s)
Abortifacient Agents, Nonsteroidal , Abortion, Induced , Mifepristone , Adult , Alprostadil/analogs & derivatives , Dinoprostone/analogs & derivatives , Drug Evaluation , Female , France , Humans , Pregnancy , Prostaglandins E, SyntheticSubject(s)
Interprofessional Relations , Nurses/psychology , Role , Female , France , Humans , Physician's Role , Social Control, FormalABSTRACT
In 2115 women seeking voluntary termination of pregnancy after 49 days of amenorrhea or less, we studied the effect of a single 600-mg dose of mifepristone (RU 486), followed 36 to 48 hours later by the administration of one of two prostaglandin analogues, either gemeprost (1 mg by vaginal suppository) or sulprostone (0.25, 0.375, or 0.5 mg by intramuscular injection). The women were monitored for four hours after prostaglandin administration. Efficacy was indicated by the complete expulsion of the conceptus without the need of an additional procedure. All other results were considered failures, and the pregnancy was then terminated by a surgical method. The overall efficacy rate was 96.0 percent (95 percent confidence interval, 95.0 to 96.8). The failures included persisting pregnancies (1.0 percent), incomplete expulsions (2.1 percent), and the need for hemostatic procedure (0.9 percent). The mean time to expulsion was significantly shorter when sulprostone was given in the high dose (4.5 hours) than when it was given in the two lower doses (13.1 and 19.3 hours) or when gemeprost was given (22.7 hours). The mean duration of uterine bleeding was 8.9 days (range, 1 to 35); one woman received a blood transfusion. Most women had transient abdominal pain after receiving prostaglandin, but there were few other side effects. We conclude that the administration of mifepristone followed by a small dose of a prostaglandin analogue is an effective and safe method for the early termination of pregnancy.
Subject(s)
Abortifacient Agents, Nonsteroidal/administration & dosage , Abortifacient Agents/administration & dosage , Abortion, Induced , Alprostadil/analogs & derivatives , Dinoprostone/analogs & derivatives , Mifepristone/administration & dosage , Abortifacient Agents, Nonsteroidal/adverse effects , Alprostadil/administration & dosage , Alprostadil/adverse effects , Dinoprostone/administration & dosage , Dinoprostone/adverse effects , Drug Evaluation , Female , Humans , Mifepristone/adverse effects , Pregnancy , Retrospective Studies , Time Factors , Uterine Hemorrhage/chemically inducedABSTRACT
This review deals with tolerance of a new macrolide, roxithromycin from data collected from a number of studies in adults. A total of 2917 adults, 2519 given roxithromycin 150 mg bid, were recruited into 17 multicentre comparative or non-comparative studies. Nine studies were double-blind, against doxycycline, erythromycin estolate (EES), lymecycline or cephradine. Overall the drug was well tolerated: side-effects possibly or probably related to roxithromycin were noted in only 4.1% (120/2917) of all patients, and in 3.1% (15/480) of elderly subjects. The gastrointestinal tolerance of roxithromycin was significantly better than that of doxycycline in four trials, and better than that of erythromycin ethylsuccinate in one study. The incidence of drug-related liver function test abnormalities following roxithromycin therapy was low and compared favourably with data published on erythromycin. Roxithromycin shows a satisfactory safety profile at the recommended daily dosage of 150 mg bid in adults.